These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 33606809)

  • 41. Germline genetic variants in men with prostate cancer and one or more additional cancers.
    Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
    Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
    Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
    Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer.
    Evans DG; van Veen EM; Byers HJ; Evans SJ; Burghel GJ; Woodward ER; Harkness EF; Eccles DM; Greville-Haygate SL; Ellingford JM; Bowers NL; Pereira M; Wallace AJ; Howell SJ; Howell A; Lalloo F; Newman WG; Smith MJ
    J Med Genet; 2022 Feb; 59(2):115-121. PubMed ID: 33758026
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pathogenic variant detection rate varies considerably in male breast cancer families and sporadic cases: minimal additional contribution beyond
    Evans DG; Burghel GJ; Howell SJ; Pugh S; Forde C; Howell A; Lalloo F; Woodward ER
    J Med Genet; 2024 Aug; 61(9):853-855. PubMed ID: 38609177
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
    Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
    Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The genetics of hereditary cancer risk syndromes in Brazil: a comprehensive analysis of 1682 patients.
    de Oliveira JM; Zurro NB; Coelho AVC; Caraciolo MP; de Alexandre RB; Cervato MC; Minillo RM; de Vasconcelos Carvalho Neto G; Grivicich I; Oliveira JB
    Eur J Hum Genet; 2022 Jul; 30(7):818-823. PubMed ID: 35534704
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.
    Cheng HF; Tsai YF; Liu CY; Hsu CY; Lien PJ; Lin YS; Chao TC; Lai JI; Feng CJ; Chen YJ; Chen BF; Chiu JH; Tseng LM; Huang CC
    Breast Cancer Res; 2023 Dec; 25(1):152. PubMed ID: 38098088
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Demographics and Clinical Decision Making in Patients with Germline Moderate Penetrance Non-BRCA Mutations in Breast Cancer Related Genes.
    Ntowe KW; Thomas SM; Dalton JC; Olunuga E; Wang T; Chiba A; Plichta JK
    Ann Surg Oncol; 2024 Oct; 31(11):7290-7300. PubMed ID: 38976158
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil.
    Cipriano NM; de Brito AM; de Oliveira ES; de Faria FC; Lemos S; Rodrigues AN; de Oliveira Lopes D; Dos Santos LL
    Breast Cancer; 2019 May; 26(3):397-405. PubMed ID: 30535581
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.
    Manchanda R; Sun L; Sobocan M; Rodriguez IV; Wei X; Kalra A; Oxley S; Sideris M; Fierheller CT; Morgan RD; Chandrasekaran D; Rust K; Spiliopoulou P; Miller RE; Crusz SM; Lockley M; Singh N; Faruqi A; Casey L; Brockbank E; Phadnis S; Mills-Baldock T; El-Khouly F; Jenkins LA; Wallace A; Ahmed M; Kumar A; Swisher EM; Gourley C; Norquist BM; Evans DG; Legood R
    J Natl Compr Canc Netw; 2024 Apr; 22(2D):. PubMed ID: 38866043
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
    Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
    J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.
    ElBiad O; Laraqui A; El Boukhrissi F; Mounjid C; Lamsisi M; Bajjou T; Elannaz H; Lahlou AI; Kouach J; Benchekroune K; Oukabli M; Chahdi H; Ennaji MM; Tanz R; Sbitti Y; Ichou M; Ennibi K; Badaoui B; Sekhsokh Y
    BMC Cancer; 2022 Feb; 22(1):208. PubMed ID: 35216584
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer.
    Rummel SK; Lovejoy L; Shriver CD; Ellsworth RE
    Breast Cancer Res Treat; 2017 Aug; 164(3):593-601. PubMed ID: 28503720
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Detection of pathogenic variants in breast cancer susceptibility genes in bilateral breast cancer.
    Evans DG; Burghel GJ; Schlecht H; Harkness EF; Gandhi A; Howell SJ; Howell A; Forde C; Lalloo F; Newman WG; Smith MJ; Woodward ER
    J Med Genet; 2023 Oct; 60(10):974-979. PubMed ID: 37055167
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
    Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
    Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast.
    Yadav S; Hu C; Nathanson KL; Weitzel JN; Goldgar DE; Kraft P; Gnanaolivu RD; Na J; Huang H; Boddicker NJ; Larson N; Gao C; Yao S; Weinberg C; Vachon CM; Trentham-Dietz A; Taylor JA; Sandler DR; Patel A; Palmer JR; Olson JE; Neuhausen S; Martinez E; Lindstrom S; Lacey JV; Kurian AW; John EM; Haiman C; Bernstein L; Auer PW; Anton-Culver H; Ambrosone CB; Karam R; Chao E; Yussuf A; Pesaran T; Dolinsky JS; Hart SN; LaDuca H; Polley EC; Domchek SM; Couch FJ
    J Clin Oncol; 2021 Dec; 39(35):3918-3926. PubMed ID: 34672684
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels.
    Feliubadaló L; López-Fernández A; Pineda M; Díez O; Del Valle J; Gutiérrez-Enríquez S; Teulé A; González S; Stjepanovic N; Salinas M; Capellá G; Brunet J; Lázaro C; Balmaña J;
    Int J Cancer; 2019 Nov; 145(10):2682-2691. PubMed ID: 30927264
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    Corrêa TS; Asprino PF; de Oliveira ESC; Leite ACR; Weis L; Achatz MI; de Oliveira CP; Sandoval RL; Barroso-Sousa R
    Genes (Basel); 2024 Jul; 15(7):. PubMed ID: 39062707
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil.
    Carraro DM; Koike Folgueira MA; Garcia Lisboa BC; Ribeiro Olivieri EH; Vitorino Krepischi AC; de Carvalho AF; de Carvalho Mota LD; Puga RD; do Socorro Maciel M; Michelli RA; de Lyra EC; Grosso SH; Soares FA; Achatz MI; Brentani H; Moreira-Filho CA; Brentani MM
    PLoS One; 2013; 8(3):e57581. PubMed ID: 23469205
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of genetic predisposition to molecular subtypes of breast cancer in Brazilian patients.
    Paixão D; Torrezan GT; Santiago KM; Formiga MN; Ahuno ST; Dias-Neto E; Tojal da Silva I; Foulkes WD; Polak P; Carraro DM
    Front Oncol; 2022; 12():976959. PubMed ID: 36119527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.